止痛贴片市场、机会、成长动力、产业趋势分析与预测，2024-2032 年

在非处方 (OTC) 贴片的显着进步以及对有效关节疼痛管理解决方案的需求不断增长的推动下，全球止痛贴片市场在 2024 年至 2032 年间将呈现 6.2% 的复合年增长率。该领域不断增长的研究和开发正在推动市场扩张。例如，2024年5月，瑞典新创公司Mucocort获得瑞典伦理审查局和瑞典医疗产品局批准，开始对其旨在治疗口疮性口炎的口内贴剂进行临床试验。本试验的主要目标是评估疼痛缓解情况。据世界卫生组织称，到 2050 年，全球 60 岁及以上人口预计将达到 21 亿，这可能会增加对疼痛管理解决方案（包括止痛贴片）的需求。

止痛贴片提供了一种方便且非侵入性的缓解疼痛的方法，使其成为寻求缓解慢性和急性疾病的消费者的首选。贴片技术和配方的创新正在提高疗效和患者满意度，为市场的大幅成长奠定了基础。

整个止痛贴片产业根据推进剂类型、罐类型、应用和地区进行分类。

就类型而言，非处方 (OTC) 止痛贴片细分市场将在 2024 年至 2032 年间经历大幅增长。最近的进步包括改进的黏附性能、更持久的效果以及增强活性成分的输送。随着消费者偏好转向非药物止痛选择，非处方药贴片因其便利性和有效性而越来越受欢迎。配方的持续创新将推动该细分市场的进一步扩张。

对于应用而言，关节疼痛领域将在预测期内显着增长。关节疼痛通常是由关节炎或受伤等疾病引起的，需要有针对性的缓解方案。专为关节疼痛设计的止痛贴片可提供局部治疗，并能以最小的副作用提供持续的缓解。透皮给药系统和製剂的进步正在增强这些贴片的有效性，使其成为患有慢性关节疼痛的个体的首选。随着人们对非侵入性疼痛管理意识的增强，对这些专用贴片的需求将会增加。

欧洲止痛贴片市场从2024 年到2032 年将呈现显着的复合年增长率。 。严格的监管框架和对消费者健康的重视正在促进先进止痛贴片的开发和采用。此外，欧洲关节疼痛的流行以及对有效非处方药解决方案的需求不断增长也促进了市场的成长。创新、监管和消费者需求的结合预计将推动止痛贴片市场在整个地区的扩张。

目录

第 1 章：方法与范围

第 2 章：执行摘要

第 3 章：产业洞察

• 产业生态系统分析
  • 影响价值链的因素
  • 利润率分析
  • 干扰
  • 未来展望
  • 製造商
  • 经销商
• 供应商格局
• 利润率分析
• 技术概览
• 重要新闻和倡议
• 监管环境
• 衝击力
  • 成长动力
    • 慢性疼痛加剧
    • 提高消费者意识
    • 体育参与趋势不断增长
    • 治疗技术的进步
  • 产业陷阱与挑战
    • 皮肤敏感性及不良反应
    • 监理合规性
• 成长潜力分析
• 波特的分析
• PESTEL分析

第 4 章：竞争格局

• 介绍
• 公司市占率分析
• 竞争定位矩阵
• 战略展望矩阵

第 5 章：市场估计与预测：按类型，2021-2032 年

• 主要趋势
• 处方贴剂
• 非处方补丁

第 6 章：市场估计与预测：按应用划分，2021-2032 年

• 主要趋势
• 肌肉疼痛
• 关节痛
• 运动伤害
• 背痛
• 轻微疼痛

第 7 章：市场估计与预测：按包装尺寸，2021-2032 年

• 主要趋势
• 1 个补丁
• 2-5 个补丁
• 5-10 个补丁
• 超过10个补丁

第 8 章：市场估计与预测：按价格范围，2021-2032

• 主要趋势
• 低的
• 中
• 高的

第 9 章：市场估计与预测：按最终用途，2021-2032 年

• 主要趋势
• 个人
• 商业的

第 10 章：市场估计与预测：按配销通路划分，2021-2032 年

• 主要趋势
• 在线的
• 离线

第 11 章：市场估计与预测：按地区划分，2021-2032 年

• 主要趋势
• 北美洲
  • 我们
  • 加拿大
• 欧洲
  • 英国
  • 德国
  • 法国
  • 义大利
  • 西班牙
  • 俄罗斯
  • 欧洲其他地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲
  • 亚太地区其他地区
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 拉丁美洲其他地区
• MEA
  • 南非
  • 沙乌地阿拉伯
  • 阿联酋
  • MEA 的其余部分

第 12 章：公司简介

• 3M Health Care
• Actavis
• BioElectronics Corporation
• Chattem, Inc.
• Endo International plc
• GlaxoSmithKline plc
• Hisamitsu Pharmaceutical Co., Inc.
• Johnson and Johnson
• Mylan N.V.
• Novartis AG
• Pfizer Inc.
• Reckitt Benckiser Group plc
• Salonpas
• Sanofi
• Teva Pharmaceutical Industries Ltd.

Global Pain Relief Patches Market will exhibit a 6.2% CAGR between 2024 and 2032, fueled by significant advancements in over-the-counter (OTC) patches and increasing demand for effective joint pain management solutions. The rising research and developments in the field are driving market expansion. For instance, in May 2024, Swedish startup Mucocort was approved by the Swedish Ethical Review Authority and the Swedish Medical Products Agency to begin a clinical trial for its intraoral patch aimed at treating aphthous stomatitis. The main goal of the trial was to evaluate pain relief. According to the World Health Organization, the global population aged 60 years and older is expected to reach 2.1 billion by 2050, which will likely increase the demand for pain management solutions, including pain relief patches.

Pain relief patches offer a convenient and non-invasive method for alleviating pain, making them a preferred choice among consumers seeking relief from chronic and acute conditions. Innovations in patch technology and formulations are enhancing efficacy and patient satisfaction, positioning the market for substantial growth.

The overall Pain Relief Patches Industry is classified based on the propellant type, can type, application, and region.

In terms of type, the over-the-counter (OTC) pain relief patches segment will experience substantial growth from 2024 to 2032. OTC patches provide accessible and user-friendly pain management solutions without the need for a prescription. Recent advancements include improved adhesion properties, longer-lasting effects, and enhanced delivery of active ingredients. As consumer preference shifts towards non-pharmaceutical pain management options, OTC patches are gaining popularity for their convenience and effectiveness. Ongoing innovations in formulations will drive further market expansion in this segment.

For application, the joint pain segment will witness significant growth over the forecast period. Joint pain, often resulting from conditions such as arthritis or injuries, requires targeted relief solutions. Pain relief patches designed specifically for joint pain offer localized treatment and can provide sustained relief with minimal side effects. Advances in transdermal delivery systems and formulations are enhancing the effectiveness of these patches, making them a preferred choice for individuals suffering from chronic joint pain. As awareness of non-invasive pain management grows, demand for these specialized patches will rise.

Europe pain relief patches market will exhibit a notable CAGR from 2024 to 2032. European countries are increasingly investing in innovative pain management solutions, driven by rising healthcare awareness and a growing aging population. Stringent regulatory frameworks and an emphasis on consumer health are fostering the development and adoption of advanced pain relief patches. Additionally, the prevalence of joint pain conditions and the increasing demand for effective OTC solutions in Europe are contributing to the market's growth. This combination of innovation, regulation, and consumer demand is expected to drive the pain relief patches market expansion across the region.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definitions
• 1.2 Base estimates and calculations
• 1.3 Forecast calculations
• 1.4 Data sources
  • 1.4.1 Primary
  • 1.4.2 Secondary
    • 1.4.2.1 Paid sources
    • 1.4.2.2 Public sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis, 2021-2032

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
  • 3.1.1 Factor affecting the value chain
  • 3.1.2 Profit margin analysis
  • 3.1.3 Disruptions
  • 3.1.4 Future outlook
  • 3.1.5 Manufacturers
  • 3.1.6 Distributors
• 3.2 Supplier landscape
• 3.3 Profit margin analysis
• 3.4 Technological overview
• 3.5 Key news and initiatives
• 3.6 Regulatory landscape
• 3.7 Impact forces
  • 3.7.1 Growth drivers
    • 3.7.1.1 Increasing chronic pain conditions
    • 3.7.1.2 Increasing consumer awareness
    • 3.7.1.3 Growing sports participation trends
    • 3.7.1.4 Advancements in treatment technology
  • 3.7.2 Industry pitfalls and challenges
    • 3.7.2.1 Skin sensitivity and adverse reactions
    • 3.7.2.2 Regulatory compliance
• 3.8 Growth potential analysis
• 3.9 Porter's analysis
• 3.10 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Competitive positioning matrix
• 4.4 Strategic outlook matrix

Chapter 5 Market Estimates and Forecast, By Type, 2021-2032 (USD Million) (Thousand Units)

• 5.1 Key trends
• 5.2 Prescription patches
• 5.3 Over-the-counter patches

Chapter 6 Market Estimates and Forecast, By Application, 2021-2032 (USD Million) (Thousand Units)

• 6.1 Key trends
• 6.2 Muscle pain
• 6.3 Joint pain
• 6.4 Sports Injuries
• 6.5 Back pain
• 6.6 Minor aches and pains

Chapter 7 Market Estimates and Forecast, By Pack Size, 2021-2032 (USD Million) (Thousand Units)

• 7.1 Key trends
• 7.2 1 patch
• 7.3 2-5 patches
• 7.4 5-10 patches
• 7.5 More than 10 patches

Chapter 8 Market Estimates and Forecast, By Price Range, 2021-2032 (USD Million) (Thousand Units)

• 8.1 Key trends
• 8.2 Low
• 8.3 Mid
• 8.4 High

Chapter 9 Market Estimates and Forecast, By End-use, 2021-2032 (USD Million) (Thousand Units)

• 9.1 Key trends
• 9.2 Individual
• 9.3 Commercial

Chapter 10 Market Estimates and Forecast, By Distribution Channel, 2021-2032 (USD Million) (Thousand Units)

• 10.1 Key trends
• 10.2 Online
• 10.3 Offline

Chapter 11 Market Estimates and Forecast, By Region, 2021-2032 (USD Million) (Thousand Units)

• 11.1 Key trends
• 11.2 North America
  • 11.2.1 U.S.
  • 11.2.2 Canada
• 11.3 Europe
  • 11.3.1 UK
  • 11.3.2 Germany
  • 11.3.3 France
  • 11.3.4 Italy
  • 11.3.5 Spain
  • 11.3.6 Russia
  • 11.3.7 Rest of Europe
• 11.4 Asia Pacific
  • 11.4.1 China
  • 11.4.2 India
  • 11.4.3 Japan
  • 11.4.4 South Korea
  • 11.4.5 Australia
  • 11.4.6 Rest of Asia Pacific
• 11.5 Latin America
  • 11.5.1 Brazil
  • 11.5.2 Mexico
  • 11.5.3 Rest of Latin America
• 11.6 MEA
  • 11.6.1 South Africa
  • 11.6.2 Saudi Arabia
  • 11.6.3 UAE
  • 11.6.4 Rest of MEA

Chapter 12 Company Profiles

• 12.1 3M Health Care
• 12.2 Actavis
• 12.3 BioElectronics Corporation
• 12.4 Chattem, Inc.
• 12.5 Endo International plc
• 12.6 GlaxoSmithKline plc
• 12.7 Hisamitsu Pharmaceutical Co., Inc.
• 12.8 Johnson and Johnson
• 12.9 Mylan N.V.
• 12.10 Novartis AG
• 12.11 Pfizer Inc.
• 12.12 Reckitt Benckiser Group plc
• 12.13 Salonpas
• 12.14 Sanofi
• 12.15 Teva Pharmaceutical Industries Ltd.